left
Hey There : )
right
company-image

Unlisted Shares

Sigachi Laboratories Ltd Essentials

As of July 24, 2024, Sigachi Laboratories Ltd, Unlisted Shares are trading at ₹43.00 per share, with a 52-week high of ₹47 and 52-week low of ₹43. The minimun lot size is 4700 shares, and the shares are traded on NSDL and CDSL.

ISIN

INE368H01018

Face Value

₹ 10

Total Share

67,53,100

Total Income

₹ 1.29 undefined

Profit After Tax

₹ ****

EPS

₹ ****

P/E

****

P/B

****

Market Capitalisation

₹ 29.04 Cr

Enterprise Value

₹ ****

Book Value

₹ 44.78

Intrinsic Value

₹ ****

Earnings Yield

4.51 %

Sector

Health Care

Sub-sector

Pharmaceuticals

Category

Small Cap

Cashflow - Operations

0.48

Sigachi Laboratories Ltd Growth

Compounded Sales Growth

1 Year

4 Year

6 Year

Compounded Profit Growth

1 Year

3 Year

6 Year

Return On Equity

2018

2021

2023

Highlights

image
  • Bulk Drugs and Drug Intermediates - Sigachi Laboratories Limited functions as a pharmaceutical company, specialising in the manufacturing of bulk drugs and drug intermediates. However, it is worth noting that apart from the pharmaceuticals business, the company is also involved in channelling funds into equity and mutual funds. Its primary investment focus revolves around sectors such as pharmaceuticals, banking, and energy. As per the segmentation shared by the company, the company earns ~50% of revenue from both the segments. 
image
  • Revenue Growth - The company's revenue has marginally increased, climbing from ₹1.23 crore in FY22 to ₹1.29 crore in FY23, indicating a growth rate of 4.9%. Over the past five years, the company's revenue has increased at a slower pace, achieving a compound annual growth rate (CAGR) of 2.77% from FY18 to FY23.
image
  • Profitability - The company has demonstrated reasonable profitability in terms of revenue, primarily due to investment business. The EBIT margin, which stood at 32.9% in FY18, has climbed to 44.2% in FY23, indicating a CAGR of 6.07%.
  • Similarly, the net profit margin has shown an increase from 99.1% in FY18 to 101.9% in FY23, showcasing a CAGR of 0.56% over the period from FY18 to FY23. Notably, a substantial portion of the company's revenue is generated from other operating activities, influencing the overall net profit margin.
image
  • Investment Thesis - In comparison to its industry peers, Sigachi Laboratories appears to be slightly overvalued with a P/E ratio of 24.23x, surpassing the current industry average of 21.03x. Additionally, the company relies significantly on income from non-operational activities, a factor that raises concerns about the long-term sustainability of the business. This reliance on non-operational income may create a less favorable perception of the company among investors, potentially impacting investment decisions

Business Rating

image

Managment

lock starlock starlock starlock starlock star
image

Accounting Practice

lock starlock starlock starlock starlock star
image

Profatibility

lock starlock starlock starlock starlock star
image

Solvency

lock starlock starlock starlock starlock star
image

Growth

lock starlock starlock starlock starlock star
image

Valuation

lock starlock starlock starlock starlock star

Overall Ratings

lock starlock starlock starlock starlock star

Recommendation

lock starlock starlock starlock starlock star

Our Team

directorImage

Smt. G. Mohan Rao

( Independent Director )

Independent Director

Quantity

Invest

, Min. Investment: ₹